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Porcine Circovirus Type 2 (PCV2) is a pathogen that has the ability to cause often devastating 24 disease manifestations in pig populations with major economic implications. How PCV2 knowledge. To this extent, the PMWS field study data was divided over a training and 166 validation cohort, and 173 biomarker genes were selected from the training set using a leave-167 one-out cross validation (Fig 3A, Table S1 ). Together, they reveal a molecular portrait of 168 PCV2-associated lymphoid lesions. This 'PCV2 disease signature' is greatly induced in the 169 validation cohort as shown by GSEA analysis, meaning upregulation of PMWS marker genes 170 and downregulation of Healthy marker genes ( Fig 3B) . Interestingly, in mediastinal lymph 171 nodes with subclinical PCV2 at 29dpi, the disease signature is dramatically repressed when 172 compared to lymph nodes of non-infected counterparts, showing once more that subclinical 173 PCV2 actively suppresses the transcriptomic recalibration that goes hand in hand with PMWS.
174
To illustrate the fidelity of the PCV2 disease signature, individual samples were classified as 175 either PMWS or healthy with the Nearest Template Prediction algorithm [20] . All samples of 176 the validation set were correctly assigned (FDR <0.05; Fig 3C) . Furthermore, all piglets from 177 the experimental study, either PCV2 free or with subclinical PCV2, were correctly classified 178 as Healthy with only one sample failing to meet the <0.05 FDR threshold (Fig 3D) .
180
biomarker genes clearly represent the immune response, which confirms from a systems level 181 that immune activation is a pivotal event in PMWS (Fig S2A) . Of note, this gene signature 182 performs better than an RNMI-based signature (Fig S2B-C) , which is more suited for small 183 sample sizes and was therefore applied for generating PorSignDB.
184
Interestingly, when probing the kinetics of the PCV2 disease signature in lymph nodes of pigs 185 experimentally infected with PCV2, S. Typhimurium or S. Choleraesuis, it is clear that these 186 two bacterial infections promote the disease signature, while in subclinical PCV2 it is 187 consistently suppressed (Fig 3E-G) Fig 6A) . Cell viability assay reveals no toxicity, excluding non-specific adverse effects of the 262 compound on infection (Fig 6B) . Chemical inhibition also displays a dose-dependent effect on 263 PCV2 infection in PK15 cells (Fig S2B-D) . Thus, robust expression of STAT3 responsive 264 genes are critical for PCV2, and hampering STAT3 activity represents an antiviral strategy 265 (Fig 6C) . 
